Archives
Direct-acting oral anticoagulants (DOACs; also called NOACs – novel oral anticoagulants) are an increasingly popular alternative to warfarin. Meanwhile, the number of obese patients requiring anticoagulation is also increasing. Because the landmark studies that established safety and efficacy for these agents specifically excluded patients with BMI ≥ 40 kg/m2 or weight > 120 kg, there […]
Read More
One of the things I did most often when I started this blog nearly 7 years ago was snag a medication list and tell you what my top priorities are to investigate. I’m going to do a little throwback and go through one tonight with my top three priorities. Here’s the medication list: Amlodipine 5 […]
Read More
FDA Approval The FDA has recently approved two generic versions of apixaban and from the amount of apixaban I’m seeing used in clinical practice, this is a great thing for overall healthcare and drug costs. Here’s the FDA’s statement. Because of this switch to generic apixaban availability as well as the recent 2019 atrial fibrillation […]
Read More
I recently did a podcast episode on heparin (which you can listen to below) and I did not mention hair loss as a potential adverse effect. In addition to heparin, it turns out there is data on other anticoagulants and this adverse effect as well. That begs the question, what should we do about this? […]
Read More
As a healthcare professional, when I hear the term heparin-induced thrombocytopenia (HIT), I get nervous. The classically taught heparin-induced thrombocytopenia (type 2) is very serious. HIT is something that needs to be closely watched for because consequences from it can include life-threatening thrombosis. Type 1 heparin-induced thrombocytopenia is considered less serious. Type 1 HIT involves […]
Read More